Evidence map›Paper›PMID 34429875›Full record

ReviewClinical and translational allergy2021

Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta-analysis.

Nor Rahimah Aini, Norhayati Mohd Noor, Mohd Khairi Md Daud, Sarah K Wise, Baharudin Abdullah

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05297760 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation

Documentation of Efficacy for Intralymphatic Allergen Immunotherapy in a Phase III Randomized, Parallel Group, Double Blind Placebo-controlled Multisite Field Trial

TypeinterventionalSponsorUniversity of ZurichRan2022 to 2025Enrolled60ConditionsRhinitis, Allergic, Seasonal, Rhinitis, Allergic, With Asthma, Allergic RhinitisArmsPolvac Grass+Rye, Saline 0.9%
NCT05960266 early_phase1completednot on this mapstarted 2023, after this paper: background citation

Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study

TypeinterventionalSponsorUniversity of ZurichRan2023 to 2024Enrolled28ConditionsHypersensitivity, Hay Fever, Rhinitis, Allergic, Seasonal, RhinoconjunctivitisArmsPolvac Grass+Rye
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Immunology of allergen immunotherapy.Immunotherapy advances · 2022
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nor Rahimah AiniDepartment of Otorhinolaryngology-Head and Neck Surgery School of Medical Sciences Universiti Sains Malaysia Health Campus Kelantan Malaysia.
Norhayati Mohd NoorDepartment of Family Medicine School of Medical Sciences Universiti Sains Malaysia Kelantan Malaysia.
Mohd Khairi Md DaudDepartment of Otorhinolaryngology-Head and Neck Surgery School of Medical Sciences Universiti Sains Malaysia Health Campus Kelantan Malaysia.
Sarah K WiseDepartment of Otolaryngology-Head & Neck Surgery Emory University School of Medicine Atlanta Georgia USA.
Baharudin AbdullahDepartment of Otorhinolaryngology-Head and Neck Surgery School of Medical Sciences Universiti Sains Malaysia Health Campus Kelantan Malaysia.ORCID https://orcid.org/0000-0001-9138-9215
Universiti Sains Malaysia · MYEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntralymphatic immunotherapy (ILIT) is a potential treatment option for allergic rhinitis (AR). We aimed to determine the efficacy (primary outcomes) and safety (secondary outcomes) of ILIT in treating patients with AR.

methodsAn electronic literature search was performed using MEDLINE and Cochrane Central Register of Controlled Trials CENTRAL (from their inception to December 2020). A random-effects model was used to estimate the pooled prevalence with 95% confidence intervals. This study is registered with PROSPERO (CRD42019126271).

resultsWe retrieved a total of 285 articles, of which 11 satisfied our inclusion criteria. There were 452 participants with age ranged from 15 to 58 years old. Intralymphatic immunotherapy was given in three doses with intervals of four weeks between doses in 10 trials. One trial gave three and six doses with an interval of two weeks. Both primary and secondary outcomes showed no difference between ILIT and placebo for all trials. There was no difference in the combined symptoms and medication score (SMD -0.51, 95% CI -1.31 to 0.28), symptoms score (SMD -0.27, 95% CI -0.91 to 0.38), medication score (SMD -6.56, 95% CI -21.48 to 8.37), rescue medication (RR 12.32, 95% CI 0.72-211.79) and the overall improvement score (MD -0.07, 95% CI -2.28 to 2.14) between ILIT and placebo. No major adverse events noted.

conclusionsIntralymphatic immunotherapy possibly has a role in the treatment of AR patients. This review found it is safe but not effective, which could be contributed by the high variation amongst the trials. Future trials should involve larger numbers of participants and report standardized administration of ILIT and outcome measures.

Indexed as

allergen‐specific immunotherapyallergic rhinitisefficacyintralymphatic immunotherapysafety

Identifiers

PMID34429875
PMCPMC8369948
OpenAlexW3196110125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.